Ingredients by Nature’s new bioflavonoid complex targets blood sugar management category

09-Oct-2019 - Last updated on 09-Oct-2019 at 15:47 GMT

A new randomized, placebo-controlled clinical trial supports the efficacy of Ingredients by Nature’s new bioflavonoid complex, branded as Eriomin, to help control blood sugar levels, inflammation and blood pressure.

The ingredient is just the first in a planned new range of ingredients built around citrus bioflavonoids, said Rob Brewster, President of IBN.

Brewster told NutraIngredients-USA that Eriomin is the first in a new range of Erio- branded products that build on the efficacy of eriocitrin in combination with other bioactives. Eriomin is composed of the citrus flavonoids eriocitrin, hesperidin, and naringin, and aims to minimize inflammation and pre-diabetes.

The ingredient will be officially launched at next week’s SupplySide West expo in Las Vegas. The first products formulated with the ingredient are expected on store shelves in early 2020, said Brewster.

Ingredients by Nature was formed in 2008 by Brewster Nutrition (which has been around since the 1930s) and its long-time strategic partner, Syntech International. The Erio- range is focused on clinical endpoints, and in the case of Eriomin, on blood glucose in prediabetic patients, said Brewster.

Building the science

Eriomin’s efficacy is supported by data from a double‐blind, randomized, controlled study, which were published in Phytotherapy Research this summer. The study included 103 prediabetics, randomly assigned to consume Eriomin at daily doses of 200, 400 800 mg for 12 weeks. A fourth group received a placebo.

Findings from the study indicated that all doses of the bioflavonoid complex led to significant reductions in blood sugar, insulin resistance, glucose intolerance, systolic blood pressure, and a raft of inflammatory biomarkers, including high sensitivity C-Reactive Protein sCRP, interleukin‐6, and TNF-alpha.

In addition, prediabetes was reversed in 24% of the evaluated study participants.

A second clinical trial is already underway involving 40 people, said Brewster.

The claims associated with the new ingredient are:

Potential structure-function claims that Eriomin can make:

Helps maintain blood glucose levels within the normal range.
Helps support normal insulin sensitivity.
Helps manage a healthy inflammation response.
Supports healthy cell function through increased antioxidant activity.

Brand extensions

With the ingredient efficacy against so many biomarkers, there is potential to optimize formulations to target other health conditions, from sports performance to joint health, and eye health, and more.

Brewster said that the next ingredient to join Eriomin will be ErioSport, which will target both traditional athletes (high endurance athletes) and the e-sports market. This will see eriocitrin combined with PMFs (polymethoxylated flavones).

Other ingredient launches include Eriovis (combination with lutein for eye health), Eriogest (for gestational diabetes), and ErioFlex (for joint health).

Personalized nutrition

According to the US Centers for Disease Control and Prevention (CDC), prediabetes affects one in every three Americans, meaning that more and more Americans are concerned about blood sugar levels.

“Blood sugar management hits home for the entire population,” said Brewster, “and because of that, Eriomin fits into the personalized nutrition paradigm.”

Source: Phytotherapy Research
Volume 33, Issue 7, Pages 1921-1933, doi: 10.1002/ptr.6386
“Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study”
Authors: C. B. Ribeiro et al.